On June 11, 2014 — Northwest Biotherapeutics (NASDAQ:NWBO) a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization (i.e., stopping the progression) of their advanced cancer. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) weekly performance is 55.15%. On last trading day company shares ended up $ 8.89. Analysts mean target price for the company is $10.05. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) distance from 50-day simple moving average (SMA50) is 46.48%.
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2021 (the “Notes”) pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (“SEC”). Acorda also intends to grant the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any. Acorda Therapeutics Inc (NASDAQ:ACOR) shares fell -8.96% in last trading session and ended the day on $32.12. Gross Margin is 80.10% and its return on assets is 3.10%. Acorda Therapeutics Inc (NASDAQ:ACOR) quarterly performance is -17.98 %.
StemCells Inc (NASDAQ:STEM) announced one promotion and three new appointments to the Company’s executive team. Stephen Huhn, M.D., F.A.C.S., F.A.A.P. has been promoted to the newly created position of vice president, CNS clinical research and chief medical officer. Joel Naor, M.D., M.B.A., M.Sc., has joined StemCells, Inc. as vice president, clinical development, ophthalmology, and will report to Dr. Stephen Huhn; Naymisha Patel has joined StemCells, Inc. as vice president, quality systems; and Mohammad A. El-Kalay, Ph.D. has joined StemCells, Inc. as vice president, process development. Dr. Huhn, Ms. Patel and Dr. El-Kalay will report to Martin McGlynn president and chief executive officer of StemCells, Inc. StemCells Inc (NASDAQ:STEM) shares moved up 5.19% in last trading session and was closed at $1.62, while trading in range of $1.53 – $1.63. StemCells Inc (NASDAQ:STEM) year to date (YTD) performance is 31.71%.
On May 28, 2014 – Genetic Technologies Limited (ADR) (NASDAQ:GENE) announced the appointment of Mr Eutillio Buccilli to the role of Chief Financial Officer, effective 2 June 2014. Genetic Technologies Limited (ADR) (NASDAQ:GENE) ended the last trading day at $1.13. Company weekly volatility is calculated as 7.57% and price to cash ratio as 12.96. Genetic Technologies Limited (ADR) (NASDAQ:GENE) showed a positive weekly performance of 4.63%.
On June 12, 2014 — Portola Pharmaceuticals Inc (NASDAQ:PTLA) announced that William Lis, chief executive officer, will present at the 2014 Wells Fargo Securities Healthcare Conference on Wednesday, June 18, at 8:20 a.m. Eastern Time in Boston. Portola Pharmaceuticals Inc (NASDAQ:PTLA) weekly performance is 17.87%. On last trading day company shares ended up $28.30. Analysts mean target price for the company is $38.50. Portola Pharmaceuticals Inc (NASDAQ:PTLA) distance from 50-day simple moving average (SMA50) is 22.59%.
Leave a Reply